Pegozafermin is a recombinant protein commercialized by 89bio, with a leading Phase III program in Hypertriglyceridemia. According to Globaldata, it is involved in 9 clinical trials, of which 5 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Pegozafermin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Pegozafermin is expected to reach an annual total of $1.4 bn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
pegozafermin (BIO89-100) is under development for the treatment of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease, liver cirrhosis, fibrosis and severe hypertriglyceridemia. It is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analog. The drug candidate acts by targeting FGF21R (composed of co-receptors FGFR1c, 2c and 3c and KLB). It is administered subcutaneously. It is developed based on glycopegylation technology to prolong the half-life of FGF21.
89bio is a clinical-stage biopharmaceutical company. It focuses on developing medicines for the treatment of nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Its lead product candidate BIO89-100, a new long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue, was formulated harnessing a proprietary glycopegylation technology that helps extend the half-life and enhance the biological functioning of native FGF21, allowing for extended-interval dosing and substantial improvement in biomarkers including body weight, blood glucose, and lipids in NASH patients. 89bio acquired a pipeline of biologic and small molecule drug candidates from Teva Pharmaceuticals. OrbiMed Israel and OrbiMed US are the founding investors of 89bio. It has operations with R&D in Herzliya, Israel. 89bio is headquartered in Menlo Park, California, the US.
The operating loss of the company was US$102.3 million in FY2022, compared to an operating loss of US$89.7 million in FY2021. The net loss of the company was US$102 million in FY2022, compared to a net loss of US$90.1 million in FY2021.
For a complete picture of Pegozafermin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.